388 HIGHER VISCERAL ADIPOSE TISSUE IS ASSOCIATED WITH LOWER RATES OF STEROID-FREE DEEP AND ENDOSCOPIC REMISSION IN PATIENTS STARTING BIOLOGIC THERAPY FOR INFLAMMATORY BOWEL DISEASES: RESULTS FROM THE CONSTELLATION STUDY

2021 ◽  
Vol 160 (6) ◽  
pp. S-79
Author(s):  
Andres J. Yarur ◽  
Alexandra Bruss ◽  
Lizbeth Nunez ◽  
Andrea Moosreiner ◽  
Daniel J. Stein ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Visceral Adipose Tissue ◽  
Inflammatory Bowel Diseases ◽  
Biologic Therapy ◽  
Endoscopic Remission ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Visceral Adipose

scholarly journals Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases

2017 ◽  
Vol 21 (5) ◽  
pp. 603-610.e3 ◽  
Author(s):  
Ashwin N. Ananthakrishnan ◽  
Chengwei Luo ◽  
Vijay Yajnik ◽  
Hamed Khalili ◽  
John J. Garber ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Gut Microbiome ◽  
Biologic Therapy ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Su2012 Impact of Abdominal Visceral Adipose Tissue on Disease Outcome in Pediatric Inflammatory Bowel Disease

2013 ◽  
Vol 144 (5) ◽  
pp. S-531
Author(s):  
Victor E. Uko ◽  
Eugene Vortia ◽  
S. Pinar Karakas ◽  
Marsha H. Kay ◽  
Claudio Fiocchi ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Adipose Tissue ◽  
Visceral Adipose Tissue ◽  
Bowel Disease ◽  
Disease Outcome ◽  
Pediatric Inflammatory Bowel Disease ◽  
Inflammatory Bowel ◽  
Visceral Adipose

scholarly journals Role of Adipose Tissue in Inflammatory Bowel Disease

2021 ◽  
Vol 22 (8) ◽  
pp. 4226
Author(s):  
Eva Karaskova ◽  
Maria Velganova-Veghova ◽  
Milos Geryk ◽  
Hana Foltenova ◽  
Veronika Kucerova ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Potential Role ◽  
Endocrine Activity ◽  
Mesenteric Fat ◽  
Principal Source ◽  
Bowel Diseases ◽  
Inflammatory Processes ◽  
Inflammatory Bowel ◽  
Visceral Adipose

Inflammatory bowel diseases (IBDs), chronic inflammatory disorders affecting the gastrointestinal tract, include Crohn’s disease and ulcerative colitis. There are increasing clinical and experimental data showing that obesity, especially visceral adiposity, plays a substantial role in the pathogenesis of IBD. Obesity seems to be an important risk factor also for IBD disease severity and clinical outcomes. Visceral adipose tissue is an active multifunctional metabolic organ involved in lipid storage and immunological and endocrine activity. Bowel inflammation penetrates the surrounding adipose tissue along the mesentery. Mesenteric fat serves as a barrier to inflammation and controls immune responses to the translocation of gut bacteria. At the same time, mesenteric adipose tissue may be the principal source of cytokines and adipokines responsible for inflammatory processes associated with IBD. This review is particularly focusing on the potential role of adipokines in IBD pathogenesis and their possible use as promising therapeutic targets.

scholarly journals Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice

2020 ◽  
Vol 92 (2) ◽  
pp. 67-73
Author(s):  
M. V. Shapina ◽  
B. A. Nanaeva
Keyword(s):  
Clinical Practice ◽  
Clinical Response ◽  
Inflammatory Bowel Diseases ◽  
Clinical Remission ◽  
Line Therapy ◽  
Steroid Dependent ◽  
Endoscopic Remission ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Real Clinical Practice

Vedolizumab is currently the only selective biological drug for the treatment of inflammatory bowel diseases (IBD). Its effectiveness and safety has been shown in clinical trials. This article presents the experience of using vedolizumab in real clinical practice in patients with various forms of ulcerative colitis (UC) and Crohns disease (CD). Materials and methods.96 patients with IBD (62 with CD and 34 with UC) were prescribed therapy with vedolizumab at a dose of 300 mg intravenously at 0, 2, and 6 weeks, and further maintenance therapy was continued every 8 weeks. Most patients had prolonged inflammation (27 (79.4%) with total UC, 35 patients with CD (56.5%) had ileocolitis), resistance to therapy, including biological drugs (19 (55.9%) in patients with UC and 49 (79.0%) in patients with CD). The effectiveness of therapy was evaluated after 3 months (based on clinical response and clinical remission), 6 and 12 months (endoscopic response and endoscopic remission were additionally evaluated). Results.After 3 months, clinical remission was observed in 62.5% and 36.6%, respectively. After 6 months, these indicators were 66.7% and 61.0%, and after 12 months, 70.8% and 61.0%, respectively. After 6 months, endoscopic remission was observed in 50.0% of UC patients and 26.8% of CD patients. After 12 months, it reached 58.3% and 31.7%, respectively. The analysis showed greater efficacy in bio-naive patients with CD (steroid-free remission after 12 months 62.5%, endoscopic remission 37.5%), as well as patients with non-stricturizing non-penetrating CD (58%). In patients with UC, vedolizumab showed the same effectiveness both in bio-naive patients (70.0%) and as a second-line therapy (71.2%). It turned out to be more effective in patients with moderate UC (76.2%) and steroid-dependent UC (77.8%). Conclusions.Vedolizumab is effective in achieving clinical response and clinical remission, as well as endoscopic response and endoscopic remission in patients with UC and CD. Given the selective mechanism of action of the drug, it can be recommended as a first-line therapy.

Sign in / Sign up

Export Citation Format

Share Document